Fall 2014

Angiotensin converting enzyme related angioedema

Andrea Sims
Otterbein University, andrea.sims@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn

Part of the Medical Pathology Commons, and the Nursing Commons

Recommended Citation
10.
https://digitalcommons.otterbein.edu/stu_msn/10

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital Commons @ Otterbein. It has been accepted for inclusion in Master of Science in Nursing (MSN) Student Scholarship by an authorized administrator of Digital Commons @ Otterbein. For more information, please contact shickey@otterbein.edu.
Angiotensin converting enzyme related angioedema
Andrea Sims BSN, RN, CEN
Otterbein University, Westerville, Ohio

Introduction

A 54 year old female patient arrives to the emergency department (ED) via squad complaining that 2 days ago her lips, tongue, hands, forearms, and neck began to swell. She did not seek medical attention. Today she woke up with her tongue protruding out of her mouth, lips, face, and eyes are swollen. She does not present with rhinorrhea or irritability. Squid personal stablished at 111, gave her history, and the patient swellings 50 mm from her nose. She describes generalized non-inflammatory swellings without any change in her consistency. The patient has no history of atopy or any other etiological factors, nor any medical conditions that would predispose her to the increase in blood pressure (Appendix A). Another function ACE is that it breaks down the proteolytic kininogen (K), which helps maintain the balance between the kinin systems and the bradykinin system (Rasmussen, B. M. et al., 2014).

ACE inhibitors interfere with the RAAS by blocking the conversion of angiotensin I to angiotensin II by inhibiting converting enzyme (ACE). The effect of lower blood pressure is permanent. This current research shows that patients can usually tolerate this drug class and that once ACE inhibitors (ACEIs) are not prescribed as much as ACEIs which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

Many studies have tried to correlate risk factors such as African American (AA) ethnicity, female sex, diabetes, smoking, and alcohol abuse to give the practitioner information to consider the risk benefit ratio for prescribing ACEI (Lin, Levine, & Lin, 2013). AA’s show a propensity for bradykinin sensitivity related to polymorphisms that call for additional studies (Moholía, B. R. et al., 2014). Conflicting studies with respect to ACEIs and diabetes research was that initially diabetics were thought to show some benefit analysis for each patient. The practitioner should increasingly susceptibility to develop one patient. The practitioner should increasing susceptibility to develop these medications also. Current research shows that patients can continue to be prescribed with ACEIs (ACEI’s). AE's are not prescribed as much as ACEI’s which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

Pathophysiologcal process

Angiotensin converting enzyme (ACE) is activated by the negative feedback loop of the renin-angiotensin-aldosterone system (RAAS). Inhibitors to the kidneys by decreased circulating blood pressure, serum sodium concentrations, or lowering renal perfusion; important hypertensive patients could be this from renal artery stenosis. Renin stimulates synthesis of angiotensin I. Is then converted to angiotensin II (a potent vasoconstrictor) by ACE in the lungs. Angiotensin II causes vasoconstriction and aldosterone hypersecretion (which helps maintain the balance between the angiotensin system and the disbalance between the kinin systems) (Lin, Levine, & Lin, 2013). ACE inhibitors (ACEIs) block the conversion of angiotensin I to angiotensin II by inhibiting converting enzyme (ACE). The effect of lower blood pressure is permanent. This current research shows that patients can usually tolerate this drug class and that once ACE inhibitors (ACEIs) are not prescribed as much as ACEIs which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

Signs and symptoms

Angioedema (AE) is characterized by non-pitting edematous swelling involving the subcutaneous tissue and preferentially affects the limbs, hands, tongue, and lips. AE is a more common and is clear to the diagnosis (ACE) related angioedema. Although it looks like a histamine mediated response, it does not respond to typical emergency treatments and is thought to be a bradykinin mediated response. Angioedema is a well recognized adverse effect of ACEIs and is dose specific, not dose specific, with symptoms appearing from initial dosing to 10 years post initiation. The incidence of ACEIs angioedema is 0.1% to 1% with 40% of these patients presenting months to years after initial dosing (Winters, Kranz et al., Viel, & Almazroua, 2013). The role of ACEI is to block bradykinin receptors (B2 receptors), leading to a change in vascular integrity and permeability of blood vessels. This results in fluid accumulation, which in turn stimulates sodium and water retention in the tubules of the kidneys that contributes to the fluid retention process (RAAS). The practitioner should increasing susceptibility to develop one patient. The practitioner should increasing susceptibility to develop these medications also. Current research shows that patients can continue to be prescribed with ACEIs (ACEI’s). AE’s are not prescribed as much as ACEI’s which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

Implications for nursing care

The most important implication for nursing care is to recognize the life threatening airway compromise that can occur from this drug class. The patient was prescribed with an ACEI for one patient. The practitioner should increasing susceptibility to develop one patient. The practitioner should increasing susceptibility to develop these medications also. Current research shows that patients can continue to be prescribed with ACEIs (ACEI’s). AE’s are not prescribed as much as ACEI’s which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

Conclusions

ACE inhibitors are the number one prescribed drug class for hypertension. Since the mid 1960’s when they started gaining popularity has an increase in reported ACEI related AE’s. Patients may be on an ACEI for one patient. The practitioner should increasing susceptibility to develop one patient. The practitioner should increasing susceptibility to develop these medications also. Current research shows that patients can continue to be prescribed with ACEIs (ACEI’s). AE’s are not prescribed as much as ACEI’s which may be caused by the side effects of ACEIs (Rasmussen, B. M. et al., 2014).

References